Letter to the Editor

Med. T. Stief*
Central Laboratory, University Hospital, D-35043 Marburg, Germany

Therapeutic fibrinogen can cause thrombosis [1]. The drug fibrinogen (considering also its galenical composition) can trigger the intrinsic phase of human coagulation. At about 0.4 g/l supplemented fibrinogen the recalcified thrombin generation increases twofold, with inter-individual variance [2]. It is therefore advisable to infuse fibrinogen only together with Low-Molecular-Weight-Heparin (LMWH) protection. Both the pro-thrombotic action of the drug fibrinogen and the anti-thrombotic action of LMWH should be monitored by the new ultra-specific, ultra-sensitive thrombin generation assays RECA or EXCA, respectively [3]. Hitherto used blunted assays should not be recommended any more.

References

*Corresponding author: Dr. Med. T. Stief, Central Laboratory, University Hospital, D-35043 Marburg, Germany, E-mail: thstief@med.uni-marburg.de

Received March 02, 2012; Accepted March 05, 2012; Published March 11, 2012


Copyright: © 2012 Stief MT. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.